Olema Pharmaceuticals Inc [NASDAQ: OLMA] stock went on an upward path that rose over 7.86% on Thursday, amounting to a one-week price increase of more than 44.72%.
Over the last 12 months, OLMA stock rose by 382.33%. The one-year Olema Pharmaceuticals Inc stock forecast points to a potential upside of 22.96. The average equity rating for OLMA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.21 billion, with 68.65 million shares outstanding and 63.38 million shares in the current float. Compared to the average trading volume of 3.19M shares, OLMA stock reached a trading volume of 4119953 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Olema Pharmaceuticals Inc [OLMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OLMA shares is $36.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OLMA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Olema Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 08, 2025. While these analysts kept the previous recommendation, Citigroup raised their target price from $20 to $21. The new note on the price target was released on August 12, 2025, representing the official price target for Olema Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $24, while Goldman analysts kept a Buy rating on OLMA stock.
The Price to Book ratio for the last quarter was 6.28, with the Price to Cash per share for the same quarter was set at 4.18.
OLMA Stock Performance Analysis:
Olema Pharmaceuticals Inc [OLMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 44.72. With this latest performance, OLMA shares gained by 222.48% in over the last four-week period, additionally plugging by 430.57% over the last 6 months – not to mention a rise of 382.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OLMA stock in for the last two-week period is set at 90.34, with the RSI for the last a single of trading hit 3.04, and the three-weeks RSI is set at 2.09 for Olema Pharmaceuticals Inc [OLMA]. The present Moving Average for the last 50 days of trading for this stock 11.12, while it was recorded at 24.88 for the last single week of trading, and 6.42 for the last 200 days.
Olema Pharmaceuticals Inc (OLMA) Capital Structure & Debt Analysis
According to recent financial data for Olema Pharmaceuticals Inc. ( OLMA), the Return on Equity (ROE) stands at -59.22%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -51.48%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Olema Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -48.25%, showcasing its effectiveness in deploying capital for earnings.
Olema Pharmaceuticals Inc (OLMA) Efficiency & Liquidity Metrics
Based on Olema Pharmaceuticals Inc’s (OLMA) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
Olema Pharmaceuticals Inc (OLMA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Olema Pharmaceuticals Inc. (OLMA) effectively leverages its workforce, generating an average of -$1562083.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.03% and a Quick Ratio of 8.03%, indicating strong ability to cover short-term liabilities.
OLMA Stock EPS
With the latest financial reports released by the company, Olema Pharmaceuticals Inc posted -0.51/share EPS, while the average EPS was predicted by analysts to be reported at 0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.68. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OLMA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Olema Pharmaceuticals Inc go to -2.30%.
Olema Pharmaceuticals Inc [OLMA] Institutonal Ownership Details
There are presently around $89.14%, or 91.76%% of OLMA stock, in the hands of institutional investors. The top three institutional holders of OLMA stocks are: BVF INC/IL with ownership of 9.14 million shares, which is approximately 16.2322%. PARADIGM BIOCAPITAL ADVISORS LP, holding 7.9 million shares of the stock with an approximate value of $$85.52 million in OLMA stocks shares; and PARADIGM BIOCAPITAL ADVISORS LP, currently with $$43.28 million in OLMA stock with ownership which is approximately 7.107%.
